In glioblastoma (GBM) and other high-grade gliomas, aberrant HDAC activity is associated with repression of MHC class I and II genes, costimulatory molecules, and interferon-responsive pathways, thereby impairing antigen presentation and facilitating immune evasion (39). This evidence concerns the gene HDAC9 and glioblastoma.